All Phenotypes Tg(EmuSR-tTa)83Bop MGI Mouse

About Help FAQ

Phenotypes associated with this allele

Allele Symbol
Allele Name
Allele ID

Tg(EmuSR-tTa)83Bop
transgene insertion 83, J Michael Bishop
MGI:3040386

Summary

5 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cx1	Trp53bp2^tm1Cdlo/Trp53bp2⁺ Tg(EmuSR-tTa)83Bop/0 Tg(tetO-MYC)36aBop/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N	MGI:3839868
cx2	Rag2^tm1Fwa/Rag2^tm1Fwa Tg(EmuSR-tTa)83Bop/0 Tg(tetO-Nfatct1*)1Grc/0	involves: 129S/SvEv * C57BL/6J * CBA/J * FVB/N	MGI:3820654
cx3	Tg(EmuSR-tTa)83Bop/0 Tg(IghMyc)22Bri/0 Tg(tetO-RNAi:Trp53)ASlowe/0	involves: C57BL * C57BL/6 * FVB/N * SJL	MGI:5521543
cx4	Tg(EmuSR-tTa)83Bop/Tg(EmuSR-tTa)83Bop Tg(tetO-NPM1/ALK,-luc)2Gde/0	involves: FVB/N	MGI:5766492
cx5	Tg(EmuSR-tTa)83Bop/Tg(EmuSR-tTa)83Bop Tg(tetO-TPM3/ALK,-luc)2Gde/0	involves: FVB/N	MGI:5766494

Allelic Composition	Trp53bp2^tm1Cdlo/Trp53bp2⁺ Tg(EmuSR-tTa)83Bop/0 Tg(tetO-MYC)36aBop/0
Genetic Background	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(EmuSR-tTa)83Bop mutation (1 available)
Tg(tetO-MYC)36aBop mutation (1 available)
Trp53bp2^tm1Cdlo mutation (0 available); any Trp53bp2 mutation (53 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased T cell derived lymphoma incidence ( J:146764 )

• incidence of T cell lymphomas is similar to that in transgenic mice wild-type for Trp53bp2

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:146764 )

• incidence of T cell lymphomas is similar to that in transgenic mice wild-type for Trp53bp2

hematopoietic system

increased T cell derived lymphoma incidence ( J:146764 )

• incidence of T cell lymphomas is similar to that in transgenic mice wild-type for Trp53bp2

immune system

increased T cell derived lymphoma incidence ( J:146764 )

• incidence of T cell lymphomas is similar to that in transgenic mice wild-type for Trp53bp2

Allelic Composition	Rag2^tm1Fwa/Rag2^tm1Fwa Tg(EmuSR-tTa)83Bop/0 Tg(tetO-Nfatct1*)1Grc/0
Genetic Background	involves: 129S/SvEv * C57BL/6J * CBA/J * FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Rag2^tm1Fwa mutation (45 available); any Rag2 mutation (119 available)
Tg(EmuSR-tTa)83Bop mutation (1 available)
Tg(tetO-Nfatct1*)1Grc mutation (0 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

hematopoietic system

abnormal double-positive T cell morphology ( J:141917 )

• 4 to 30% DP thymocytes appear allowing some DN cells to progress to the DP state, which is fewer than in wild-type mice but more than in Rag2 null mice

immune system

abnormal double-positive T cell morphology ( J:141917 )

• 4 to 30% DP thymocytes appear allowing some DN cells to progress to the DP state, which is fewer than in wild-type mice but more than in Rag2 null mice

Allelic Composition	Tg(EmuSR-tTa)83Bop/0 Tg(IghMyc)22Bri/0 Tg(tetO-RNAi:Trp53)ASlowe/0
Genetic Background	involves: C57BL * C57BL/6 * FVB/N * SJL

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(EmuSR-tTa)83Bop mutation (1 available)
Tg(IghMyc)22Bri mutation (1 available)
Tg(tetO-RNAi:Trp53)ASlowe mutation (0 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

decreased tumor-free survival time ( J:123006 )

• mutants become moribund without a large peripheral tumor burden, with a median survival of 82 days

neoplasm

increased lymphoma incidence ( J:123006 )

• mutants develop lymphoma, with latency of tumorigenesis reduced compared to single Tg(IghMyc)22Bri/0 mice

• lymphoma-bearing mice treated with doxycycline at the onset of paralysis regain full movement within 2 days of doxycycline treatment, show tumor involution, and live for a further 24-64 days before tumors relapse

growth/size/body

enlarged spleen ( J:123006 )

• spleen is enlarged and taken over by B220+ IgM- (pre-B) tumor cells, with lymphoma dissemination into the lymph nodes and liver

hematopoietic system

enlarged spleen ( J:123006 )

• spleen is enlarged and taken over by B220+ IgM- (pre-B) tumor cells, with lymphoma dissemination into the lymph nodes and liver

immune system

enlarged spleen ( J:123006 )

• spleen is enlarged and taken over by B220+ IgM- (pre-B) tumor cells, with lymphoma dissemination into the lymph nodes and liver

behavior/neurological

hindlimb paralysis ( J:123006 )

• partial hind leg paralysis is seen in some mutants, most likely attributed to lymphoma

Allelic Composition	Tg(EmuSR-tTa)83Bop/Tg(EmuSR-tTa)83Bop Tg(tetO-NPM1/ALK,-luc)2Gde/0
Genetic Background	involves: FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(EmuSR-tTa)83Bop mutation (1 available)
Tg(tetO-NPM1/ALK,-luc)2Gde mutation (0 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:160236 )

• mice die within a mean latency of 4 weeks when dox is removed at the newborn stage

embryonic lethality, complete penetrance ( J:160236 )

• embryonic lethality is seen in the absence of doxycycline (dox)

immune system

enlarged spleen ( J:160236 )

• splenomegaly in mice when dox is removed in newborns

enlarged lymph nodes ( J:160236 )

• generalized lymphadenopathy in mice when dox is removed in newborns

growth/size/body

postnatal growth retardation ( J:160236 )

• mice are growth retarded when dox is removed in newborns

enlarged spleen ( J:160236 )

• splenomegaly in mice when dox is removed in newborns

hematopoietic system

enlarged spleen ( J:160236 )

• splenomegaly in mice when dox is removed in newborns

integument

abnormal skin morphology ( J:160236 )

• induction of transgene expression by removal of dox in newborns results in the development of a skin disease affecting the snout and paws, first detectable at 3 weeks of age

abnormal dermal layer morphology ( J:160236 )

• lymphomatous infiltration is sometimes seen in the dermis below the keratoacanthoma-like lesions

epidermal hyperplasia ( J:160236 )

• mice exhibit skin nodules of a hyperplasia of the epidermis when dox is removed at the newborn stage, suggesting a keratoacanathoma-like lesion

• mice that are moribund with tumors and treated with dox for 12 days to suppress transgene expression exhibit a clearing of skin lesions and regrowth of hair within 3 weeks

• treatment of mice with an ALK phosphorylation inhibitor PF-2341066 results in a progressive clearing of skin lesions

neoplasm

increased leukemia incidence ( J:160236 )

• mice develop aggressive lymphoma/leukemia when dox is removed in newborns

• lymphoma/leukemia are derived from B cells

increased B cell derived lymphoma incidence ( J:160236 )

• mice develop aggressive lymphoma/leukemia when dox is removed in newborns

• lymphoma/leukemia are derived from B cells

• transplantation of mutant bone marrow into recipient mice results in the development of B-cell lymphoma without skin lesions

• mice that are moribund with tumors and treated with dox for 12 days exhibit tumor regression

• treatment of mice with an ALK phosphorylation inhibitor PF-2341066 results in tumor regression

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
non-Hodgkin lymphoma		DOID:0060060	OMIM:605027	J:160236

Allelic Composition	Tg(EmuSR-tTa)83Bop/Tg(EmuSR-tTa)83Bop Tg(tetO-TPM3/ALK,-luc)2Gde/0
Genetic Background	involves: FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(EmuSR-tTa)83Bop mutation (1 available)
Tg(tetO-TPM3/ALK,-luc)2Gde mutation (0 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:160236 )

• mice die within a mean latency of 4 weeks when dox is removed at the newborn stage

embryonic lethality, complete penetrance ( J:160236 )

• embryonic lethality is seen in the absence of doxycycline (dox)

hematopoietic system

enlarged spleen ( J:160236 )

• splenomegaly in mice when dox is removed in newborns

integument

abnormal skin morphology ( J:160236 )

• induction of transgene expression by removal of dox in newborns results in the development of a skin disease affecting the snout and paws, first detectable at 3 weeks of age

abnormal dermal layer morphology ( J:160236 )

• lymphomatous infiltration is sometimes seen in the dermis below the keratoacanthoma-like lesions

epidermal hyperplasia ( J:160236 )

• mice exhibit skin nodules of a hyperplasia of the epidermis when dox is removed at the newborn stage, suggesting a keratoacanathoma-like lesion

• mice that are moribund with tumors and treated with dox for 12 days to suppress transgene expression exhibit a clearing of skin lesions and regrowth of hair within 3 weeks

immune system

enlarged spleen ( J:160236 )

• splenomegaly in mice when dox is removed in newborns

enlarged lymph nodes ( J:160236 )

• generalized lymphadenopathy in mice when dox is removed in newborns

neoplasm

increased leukemia incidence ( J:160236 )

• mice develop aggressive lymphoma/leukemia when dox is removed in newborns

• lymphoma/leukemia are derived from B cells

increased B cell derived lymphoma incidence ( J:160236 )

• mice develop aggressive lymphoma/leukemia when dox is removed in newborns

• lymphoma/leukemia are derived from B cells

• transplantation of mutant bone marrow into recipient mice results in the development of B-cell lymphoma without skin lesions

• mice that are moribund with tumors and treated with dox for 12 days exhibit tumor regression

growth/size/body

enlarged spleen ( J:160236 )

• splenomegaly in mice when dox is removed in newborns

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
non-Hodgkin lymphoma		DOID:0060060	OMIM:605027	J:160236

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 11/12/2024 MGI 6.24